Health Economics›Breast cancer›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Breast cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Olaparib monotherapy Variant #01	BRCA	R 59 224	28d	7.0 mo	19.3 mo	8	R 473 792 PFS proxy	2
Eribulin monotherapy Variant #01	BRCA	R 24 243	21d	4.1 mo	13.1 mo	6	R 145 460 PFS proxy	21
Gemcitabine monotherapy Variant #20	BRCA	R 14 213	56d	4.6 mo	11.2 mo	3	R 42 639 PFS proxy	15
Carboplatin and Paclitaxel (CP) Variant #38	BRCA	R 5 031	21d	12.6 mo	28.2 mo	19	R 95 583 PFS proxy	2
Capecitabine monotherapy Variant #17	BRCA	R 2 219	21d	4.5 mo	15.6 mo	7	R 15 535 PFS proxy	33
Carboplatin monotherapy Variant #01	BRCA	R 1 231	21d	~5.8 mo	~21.0 mo	~9	~R 11 076 PFS proxy · indirect	7
Vinorelbine monotherapy Variant #01	BRCA	R 583	21d	4.0 mo	10.8 mo	6	R 3 500 PFS proxy	17
Docetaxel monotherapy N/A - secondary systemic drug	BRCA	R 243	28d	4.7 mo	11.4 mo	6	R 1 459 PFS proxy	5
Talazoparib monotherapy Variant #01 Partial	BRCA	—	28d	8.6 mo	19.3 mo	10	—	2

9 of 9 regimens shown